Novavax, Inc. (NASDAQ:NVAX - Get Free Report)'s stock price rose 3.8% during mid-day trading on Friday . The company traded as high as $5.70 and last traded at $5.81. Approximately 2,094,600 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 8,042,809 shares. The stock had previously closed at $5.60.
Wall Street Analysts Forecast Growth
NVAX has been the subject of a number of analyst reports. TD Cowen upgraded shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Novavax currently has a consensus rating of "Hold" and a consensus price target of $18.00.
View Our Latest Stock Report on Novavax
Novavax Trading Up 7.0 %
The company has a market cap of $1.09 billion, a PE ratio of -2.99, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. The stock has a fifty day simple moving average of $7.67 and a two-hundred day simple moving average of $8.98.
Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. As a group, equities research analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Novavax
A number of institutional investors and hedge funds have recently bought and sold shares of NVAX. GF Fund Management CO. LTD. acquired a new stake in shares of Novavax during the fourth quarter valued at about $27,000. Spire Wealth Management acquired a new stake in Novavax during the 4th quarter valued at approximately $29,000. New Age Alpha Advisors LLC purchased a new stake in Novavax during the 4th quarter worth approximately $35,000. KBC Group NV raised its position in shares of Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, TigerOak Management L.L.C. purchased a new position in shares of Novavax during the 4th quarter valued at approximately $86,000. Hedge funds and other institutional investors own 53.04% of the company's stock.
Novavax Company Profile
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Stories
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
